Identification of a pharmacological approach to reduce ACE2 expression and development of an in vitro COVID-19 viral entry model

Because of rapid emergence and circulation of the SARS-CoV-2 variants, especially Omicron which shows increased transmissibility and resistant to antibodies, there is an urgent need to develop novel therapeutic drugs to treat COVID-19. In this study we developed an in vitro cellular model to explore...

Descripción completa

Detalles Bibliográficos
Autores principales: Endo, Yukinori, Hickerson, Brady T., Ilyushina, Natalia A., Mohan, Nishant, Peng, Hanjing, Takeda, Kazuyo, Donnelly, Raymond P., Wu, Wen Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733118/
https://www.ncbi.nlm.nih.gov/pubmed/36514715
http://dx.doi.org/10.1016/j.jve.2022.100307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733118/
https://www.ncbi.nlm.nih.gov/pubmed/36514715
http://dx.doi.org/10.1016/j.jve.2022.100307

Ejemplares similares